19:06 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Jan....
22:05 , Jan 3, 2019 |  BC Extra  |  Financial News

Venture roundup: Cabaletta, Thousand Oaks, Sojournix

Autoimmune company Cabaletta Bio Inc. (Radnor, Pa.), CMC services play Thousand Oaks Biopharmaceuticals Inc. (Haimen, China) and women's health company Sojournix Inc. (Waltham, Mass.) each announced venture rounds of at least $44 million on Thursday....
07:00 , Apr 17, 2006 |  BioCentury  |  Finance

Scorched earth

Matt Murray says he was fired from his sellside job at Rodman & Renshaw because he wanted to downgrade his rating of a biotech banking client. The email stream he has provided to regulators, lawmakers...
08:00 , Mar 28, 2005 |  BioCentury  |  Finance

Ebb & Flow

When Guilford (GLFD) licensed its GPI 1485 neuroimmunophilin ligand to Symphony Neuro Development last year, the move was designed to let GLFD focus on starting Phase III trials of its Aquavan sedative. But the four...
08:00 , Jan 10, 2005 |  BioCentury  |  Finance

Steady as she goes

There are three very different piles of tea leaves for 2005. The bad pile has all the negative publicity over drug safety and uncertainty over how FDA will be run as a result. The neutral...
08:00 , Nov 1, 2004 |  BioCentury  |  Finance

Ebb & Flow

Although investors and analysts always push for more transparency, it's no guarantee that they'll like what they see when the veil parts. Such was the case with ImClone (IMCL) last week. The company provided relatively...
07:00 , Jul 1, 2002 |  BioCentury  |  Finance

2Q Financial Markets Review: Hard decisions loom

The biotech selloff has contracted multiples for profitable companies and lowered technology values for development stage companies. While the former will survive - and even trade up if a multiple expansion occurs - there are...
07:00 , May 20, 2002 |  BioCentury  |  Finance

Ebb & Flow

Back in February, a table in BioCentury showed how much value would be lost in big cap biotech if the group's price-to-earnings multiples contracted to those of big pharma (see BioCentury, Feb. 19). At the...
07:00 , Jul 2, 2001 |  BioCentury  |  Finance

2Q Financial Markets Review: Identifying momentum

In the 1980s and most of the 1990s, investors looking to generate 15-plus percent, beat-the-NASDAQ-type returns didn't have to look much beyond the "A-B-Cs" of the industry - Amgen Inc. , Biogen Inc. , Chiron...
07:00 , Oct 4, 1999 |  BioCentury  |  Finance

3Q Market Review: Biobulls make their case

Overlooking the shaky conditions of the overall stock markets in the past two weeks, the reality is that the biotech sector has been on a tear. The BioCentury 100 was up 11 out of the...